The FDA finalized a 2010 guidance on using noninferiority trials to establish the effectiveness of new drugs and biologics. Published in Tuesday's Federal Register, the guidance advises on when noninferiority studies can provide interpretable results, how to choose the noninferiority margin and how to test the hypothesis.